Syndax Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
11analysts covering
FY Revenue (est.)
$316.3Mnext fiscal year
FY EPS (est.)
-$1.95next fiscal year
Monitoring Framework
Key Performance Indicators
Revuforj (revumenib) Net Revenue Quarterly48.9M
Niktimvo (axatilimab) Collaboration Revenue Quarterly15.9M
Total Revenue Quarterly64.9M
Cash, Cash Equivalents, and Short-Term Investments Quarterly352.1M
Watch Items
- Topline data from MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF)Trigger: Second half of 2026Action: Evaluate clinical efficacy and safety profile to determine registrational path in IPF.
- Global enrollment progress in EVOLVE-2 and REVEAL-ND Phase 3 frontline trials of revumenibTrigger: Ongoing throughout 2026Action: Monitor site activation and patient enrollment rates to ensure timelines for frontline AML expansion remain on track.
- Launch of RAVEN Phase 2 collaborative trial of revumenib in newly diagnosed KMT2Ar patientsTrigger: Initiation in 2026Action: Track first patient dosed and initial safety/tolerability signals of the triplet combination.
Research as of 20 Jun 2026